Research guides
Comparison guides, regulatory explainers, and evidence-first articles for readers who want the context before the claim.
23
guides
215
citations
8
topics
ll-37 A research-backed guide to LL-37 peptide claims, topical chronic-wound trials, antimicrobial biology, infection-marketing limits, FDA compounding cautions, and safety unknowns.
kpv A cautious review of KPV peptide gut-inflammation claims, PepT1 biology, cell and animal evidence, oral-delivery research, adjacent human data, and FDA safety cautions.
ascension peptides A practical Ascension Peptides review focused on product range, COA due diligence, research-use-only boundaries, buying checks, and when our referral link makes sense.
ghk-cu A source-backed guide to GHK-Cu skin and hair claims, topical cosmetic evidence, human study limits, FDA compounding context, injectable-route risks, and how to read copper-peptide marketing.
mots-c A research-backed review of MOTS-c peptide weight-loss, insulin-sensitivity, exercise, and longevity claims, including preclinical findings, human biomarker studies, a 2026 Phase 2a trial record, and safety limits.
ss-31 A research-backed guide to SS-31 and elamipretide, Forzinity's Barth syndrome approval, mitochondrial evidence, primary mitochondrial myopathy trial limits, safety warnings, and longevity claims.
thymosin alpha-1 A source-backed review of thymosin alpha-1 immune-support claims, TESTS phase 3 sepsis findings, older trial evidence, regional status, FDA compounding warnings, and safety limits.
pt-141 A research-backed guide to PT-141 side effects, Vyleesi label warnings, HSDD trial outcomes, blood-pressure effects, nausea, pigmentation risk, and the difference between approved bremelanotide and research-market products.
kisspeptin A source-backed review of kisspeptin for fertility, testosterone, and libido claims, including human endocrine studies, IVF research, HSDD data, compounding risk warnings, and where evidence remains early.
tesamorelin A research-backed guide to tesamorelin for visceral fat, HIV-associated lipodystrophy evidence, liver-fat data, GLP-1 comparisons, safety warnings, and weight-loss claim limits.
melanotan ii A research-backed guide to Melanotan II side effects, tanning-peptide claims, small human studies, online-use data, regulator warnings, and case-report safety signals.
glp-1 A research-literacy guide to GLP-1 withdrawal and maintenance evidence from semaglutide STEP trials, tirzepatide SURMOUNT-4, and newer weight-regain analyses.
glp-1 A source-backed guide to common GLP-1 adverse effects and serious safety signals, including GI effects, thyroid warnings, gallbladder disease, pancreatitis, kidney injury, retinopathy, and compounded-product risks.
glp-1 A plain-English guide to GLP-1 compounding rules after shortage changes, including 503A, 503B, essentially-copy limits, salt forms, dosing errors, and red flags.
comparison A source-aware comparison of growth-hormone peptide topics across receptor biology, evidence strength, FDA status, compounding safety concerns, and marketing claims.
comparison A research-backed comparison of retatrutide, tirzepatide, and semaglutide across receptor targets, approval status, obesity trials, cardiometabolic evidence, and open questions.
reconstitution A measurement-first guide to peptide reconstitution math, including concentration, milligrams, micrograms, milliliters, syringe units, and common calculation mistakes.
regulatory literacy A practical framework for separating FDA-approved peptide medicines, clinical-stage investigational drugs, compounded products, and research peptides sold online.
comparison A source-backed comparison of three popular recovery peptide topics, with a focus on what is human evidence, what is preclinical, and where marketing gets ahead of the data.
comparison A source-backed comparison of semaglutide, tirzepatide, retatrutide, cagrilintide, and related incretin or amylin-based peptide medicines.
comparison A practical comparison of approved GLP-1 and incretin drugs, other approved peptide medicines, and research-market peptides with thinner evidence.
research literacy A practical guide to reading peptide research without overinterpreting study design, endpoints, controls, safety reporting, or early animal and cell data.
team note A short note from the PD Team on why Peptides Defined exists, how we plan to cover peptide topics, and what readers can expect next.
Guide updates
A quiet update list for new comparison guides, calculator updates, and evidence notes. No dosing advice or sales emails.
